Liang Cheng, President of International Society of Urological Pathology, Vice Chair for Translational Research at the Warren Alpert Medical School of Brown University, shared on LinkedIn:
“Can you predict FGFR3 mutations in Bladder Cancer based on morphology? I am pleased to share this article by Dr. Katrina Collins, which will appear in the August 2026 issue of Laboratory Investigation.
In this study, we found FGFR3 alterations in 17% of urothelial carcinomas, with S249C and Y373C accounting for most mutations. Remarkably, 76% of FGFR3-altered tumors exhibited variant histology, most commonly micropapillary (39%) and squamous differentiation (21%). Both morphologic patterns were exclusively associated with the canonical S249C or Y373C hotspot mutations.
Although morphology cannot replace molecular testing, recognizing these histologic patterns may help identify patients most likely to benefit from FGFR3 testing and targeted therapy, particularly in advanced urothelial carcinoma.”
Other articles about GU Oncology on OncoDaily.
